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Background: We examined the year-to-year change in FEV1 for individuals and the overall cystic fibrosis population to better understand how
individual trends may differ from population trends.
Methods: We calculated individual yearly changes using the largest annual FEV1 percent predicted (FEV1%) measurement in 20,644 patients
(6–45 years old) included in the Epidemiologic Study of Cystic Fibrosis. We calculated yearly population changes using age-specific medians.
Results: FEV1% predicted decreased 1–3 points per year for individuals, with maximal decreases in 14–15 year olds. Population changes agreed
with individual changes up to age 15; however after age 30, yearly population change approximated zero while individual FEV1% predicted
decreases were 1–2 points per year.
Conclusions: Adolescents have the greatest FEV1% predicted decreases; however, loss of FEV1 is a persistent risk in 6–45 year old CF patients.
Recognizing individual year-to-year changes may improve patient-specific care and may suggest new methods for measuring program quality.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pulmonary function; Annual trends1. Introduction
Forced expiratory volume in 1s (FEV1) is the most important
single factor predictive of survival in cystic fibrosis (CF) [1–5].
FEV1 has a major impact on clinical decision making and serves
as a critical endpoint for studies to improve outcomeswith CF [6].
Declines in FEV1 have been found to be predictive of increased
hospitalizations and death in patients with chronic obstructive
pulmonary disease [7,8]. In CF, the predictive ability of rates of⁎ Corresponding author. Tel.: +1 801 585 2804; fax: +1 801 585 2661.
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doi:10.1016/j.jcf.2010.04.002decline in FEV1 for death have been hypothesized and some
evidence found for poorer outcomes with more rapid rates of
decline [9–11], but several recent large studies of CF have failed
to confirm such an association [2,3,12,13], and the finding can be
elusive in other pulmonary diseases [14,15]. Nevertheless, more
rapid rates of decline are found to be important in understanding
disease for other clinical outcomes in CF as well as in other lung
diseases [16–20].
Cross-sectional measurements of FEV1 are a common basis
for understanding FEV1 trends over time [21], and clinicians are
encouraged to use these trends to understand prognosis and plan
therapy. Patients and their families are invited to review lung
function trends as a measure of the quality of care provided in
each certified CF Care Center in the United States [22]. However,
aggregated population results for lung function decline may bed by Elsevier B.V. All rights reserved.
Table 1
Methods for calculating change in FEV1% from one age to the next
*.
Method Ages
14 to 15
(and prior)
15 to 16 16 to 17 17 to
18
18–19
(and later)
CFF
algorithm
Females W–W W–H H–H H–H H–H
Males W–W W–W W–W W–H H–H
Current
analysis
Females W–W W–W H–H H–H H–H
Males W–W W–W W–W H–H H–H
*CFF=Cystic Fibrosis Foundation [3]; W=Wang, et al. Method [7];
H=Hankinson, et al. method [8].
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[23–25], especially when derived from cross-sectional data
[23,25–27], and individual assessments of lung disease progres-
sion may provide information not detectable in aggregated
analyses [26,27].
We analyzed data from the Epidemiologic Study of Cystic
Fibrosis (ESCF) [16] to discover if there are particular age
groups that are prone to more rapid falls in FEV1 percent
predicted (FEV1%). The ESCF data provide a uniquely precise
record of frequent lung function measurements that are required
for a study of individual decline in lung function [23,25,26].
Using this data, we examined FEV1% from one selected year of
age to the next year of age both in individuals and in the
population to understand how individual experiences may differ
from population experience [23,26,27] in the setting of CF.
Knowledge of likely, individual outcomes from one year of age
to the next may enable physicians to improve and tailor the
intensity and nature of treatments to individuals to optimize
therapy, minimize treatment burden and improve outcomes.
2. Methods
The data were obtained from ESCF, an encounter-based,
longitudinal, multi-center study designed to understand the
natural history of patients with CF in North America [16].
Written informed consent was obtained according to the
policies governing research at each participating institution.
Data were collected from 1994 to 2005. Baseline information
such as birth date, sex, and race/ethnicity were recorded when
the patient enrolled in the study. Pulmonary function test (PFT)
results, height, weight, and the date of each exam were recorded
in a prospective manner for each patient visit.
Age at the time of PFT was calculated as of the patient's last
birthday, and FEV1 measurements were included in this
analysis for patient ages 6 through 45. We excluded measure-
ments before age 6 because of a lack of standardized PFT
methods and after age 45 because of insufficient data. We
defined FEV1% for a patient's year of age as the largest value
during the year in which the patient had three or more FEV1%
values (for example, the largest value among the three or more
measurements performed while the patient was age 8). We
chose the best FEV1% as being most reflective of the patient's
true baseline lung function, and we required at least three values
during the year in order to further reduce the likelihood of using
atypically low values to represent that patient's lung function at
that age. For consecutive years that a patient had this single
largest FEV1% value available, the year-to-year change
between consecutive ages was calculated (e.g., the change
from age 8 to age 9 was calculated using the single largest
FEV1% during each year of age).
The United States Cystic Fibrosis Foundation (CFF) Patient
Registry algorithm was used to determine FEV1% [21].
Specifically, the Wang et al. method [28] was used for females
through the age of 15 years and the Hankinson et al. method
[29] was used for females aged≥16 years. For males, the Wang
et al. method was used through the age of 17 years and
Hankinson et al. method for ages ≥18 years. Use of differentnormalization equations for measurements taken at different
time points could introduce artifact into our analysis. Thus, we
performed sensitivity analyses and confirmed that using
different calculation methods [28–30] had an effect on the
FEV1% changes during mid-adolescence, an age period of
particular interest. Because of this finding, additional sensitivity
analyses of changes in FEV1% from one age to the next were
calculated using only one method within each sex (Table 1).
All eligible FEV1% values (as described above) were
included to calculate the population mean, median, and
distribution of FEV1% for each age from 6 to 45. From these
data, the year-to-year changes in the population median FEV1%
were determined. In addition, the mean, median and distribution
of year-to-year individual changes in FEV1% were calculated.
These individual changes were also characterized by the percent
of patients with an absolute decrease in FEV1% of ≥5 points
and ≥10 points.
The impact of several assumptions was explored using
sensitivity analyses. First, we relaxed the criterion of requiring
three FEV1% measurements during an age year to requiring
only one measurement to examine potential bias related to
frequency of patient monitoring. Second, we examined the
potential for bias in year-to-year individual changes due to
censoring (loss to follow-up, lung transplantation, or death)
immediately after two consecutive FEV1% measurements by
examining the effect of restricting calculations to patients with a
minimum of two additional years of data beyond the pair of
years evaluated.
3. Results
This analysis included 20,664 patients contributing at least
1 year of data for calculation of aggregated measures of
FEV1%, with 4013 patients at 6 years old, a high of 5103
patients at 11 years old, and a steady decrease in patient
numbers to 175 patients at 45 years old (data shown as vertical
bars in Fig. 1). For the analyses of individual year-to-year
changes, there were 2816 patients with data for consecutive
ages 6 to 7, a high of 3645 patients with data for ages 10 to 11,
and 118 patients for ages 44 to 45. Age pairs older than 45 had
fewer than 100 patients, so they were not included in this
analysis.
Summary statistics of the aggregated population data show
that after an initial period of modest decline in FEV1%, there is a
steeper decline from early adolescence to early adulthood
Fig. 1. Population FEV1 percent predicted by age. The largest FEV1% value for each year of age is shown in aggregated form. Data for patients included in the data
base for multiple years are included in the calculations for every year of age available. FEV1 was normalized to percent predicted values calculated using methods of
Wang, et al. [28] and Hankinson, et al. [29] in accordance with CF Foundation Registry convention [21]. The bold line shows the median population value at each age,
while circles represent the mean at each age. To provide a sense of the variation seen within the population for each year of age, lighter solid lines show the 25th and
75th percentiles, and dotted lines show the 10th and 90th percentiles. The number of patients contributing data for each year of age is shown by the superimposed bar
chart at the bottom of the graph (right axis).
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after which the FEV1% appears relatively stable (Fig. 1).
Examination of FEV1% values for consecutive years of age
reveals that for most ages the individual year-to-year change is a
drop of 1 to 3 FEV1% points (Fig. 2a). The mean and median of
individual year-to-year changes are always negative, with
progressively worse declines until about age 15 and smaller
declines through adulthood to age 45. Through age 15, the change
in median FEV1% based on aggregated population data agrees
well with individual data for year-to-year change (Fig. 2b). In
contrast, the change in median FEV1% based on the population
data shows higher variability after age 15, but it approximates
zero in patients over age 30.
A substantial fraction of patients have relatively large
individual year-to-year drops in FEV1% (Fig. 3). For every
age pair from 6 to 7 through 41 to 42, over 20% of patients have
decreases of≥5 FEV1% points. At the peak age of 15 to 16, this
approaches 50% of patients. For each age pair from 6 to 7
through 26 to 27, over 10% of patients have drops of ≥10
FEV1% points, again peaking at ages 15 to 16, when almost 25%
of patients have a decrease this large. This mirrors the results of
year-to-year drops in median FEV1% shown in Fig. 2a.
All of our results were stable through sensitivity analyses
designed to detect bias introduced by non-uniform numbers of
repeated measurements each year, by the effects of differing
methods of FEV1% calculation, and by the effects of early
censoring from the study due to loss to follow-up, lung
transplantation, or death. Repeated analyses after splitting the
data set into two cohorts, 1994–1999 and 2000–2005 showed no
secular trends. Stratification of the data by gender revealed verysimilar behavior in year-to-year changes in lung function. Using
CF Foundation methods to normalize lung function revealed that
male patients had their greatest drop in lung function in the age
14–15 cohort while females had their greatest drop in the age
15–16 cohort. Using Stanojevic normalization equations, both
males and females had their maximal year-to-year changes in the
age 19–20 cohort.
4. Discussion
A population-based view of FEV1 in CF is helpful for
understanding the impact of therapy on a population and is useful
for assessing quality improvement [21,22,31]. This study
demonstrates the importance of considering individual patient
experiences with year-to-year change in FEV1% in addition to the
aggregated population experience. Our population results (Fig. 1)
are consistent with previously published observations [21].
However, we show that individual trends in FEV1% year-to-
year differ from the cross-sectional population trends and that
individuals can have enormous variance from cross-sectional
trends. The fact that cross-sectional results do not always
accurately represent longitudinal changes in pulmonary function
has been previously observed in healthy male adults [23], and the
issue has been considered in a number of subsequent studies in
various pulmonary diseases [8,11,14,15,17–20,26,27,32]. Such
differences between individuals and the overall population may
change assessments of individual prognosis and the nature and
intensity of patient-specific treatment plans. Most importantly for
clinical practice, knowledge of likely near-term lung function
trajectory allows optimization of therapy on an individual basis,
Fig. 2. a. Individual changes in FEV1 percent predicted by age. FEV1%s at each age were calculated using modified methods of Wang, et al. [28] and Hankinson, et al.
[29] (see methods in text and Table 1). The bold line shows the median of the individual year-to-year changes for each age group, while solid circles with bars represent
the mean and 95% confidence interval at each age. The lighter curves represent the 25th and 75th percentiles and provide a sense of the variance for each age group.
b. Median of individual changes in FEV1% and change in population median of FEV1% by age. A curve with squares and a light line showing the change in the
population median FEV1% from year-to-year is superimposed on the median of individual year-to-year changes at each age (bold curve). The population aggregate
year-to-year changes parallel individual changes through early adulthood. However following approximately age 30, the aggregated population changes are more
optimistic than observed for individuals (see text for further discussion).
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the aggregated trajectory and provides additional incentive for
patients and their caretakers to adhere to often burdensome
therapies.
The data indicate that adolescents are at higher risk of
decreases in lung function than younger patients or adults. The
propensity to lose lung function year-to-year increased progres-
sively from age 6 to age 15. Others have found FEV1% in mid-adolescence to be of particular importance in predicting survival
with CF [3], increasing the level of concern over adolescent year-
to-year lung function losses. Adolescents had twice the median
year-to-year loss in lung function as adults and thus had the
highest likelihood of large drops in lung function (Fig. 3). Our
sensitivity analyses show that this is unlikely to be due to survivor
bias and highlights the need to better understand the challenges
posed by the combination of adolescence and CF and, perhaps
Fig. 3. Large decreases in FEV1% by age. The individual year-to-year changes in FEV1% at each age were calculated as described in the text and Table 1. The bold
curve shows the percent of patients with a decrease of 5% or more in FEV1% during a single year-to-year age group. The lighter curve reveals the percentage of patients
with decreases of 10% or more in FEV1%. Regardless of age group, substantial numbers of individual patients with CF suffer large drops in FEV1% (see text for further
discussion).
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function begin around ages 9 to 11 and continue through
adolescence (Fig. 2, panels a and b).
Although patients who reach adulthood have a decreased
tendency to lose FEV1%, the median loss remains nearly 2
percentage points per year through middle adulthood (Fig. 2,
panel a). This effect sharply contrasts with results from the
analysis of aggregated population data (Fig. 2, panel b) that
show that median FEV1% change fluctuates and approximates
zero among adults. This contrast may potentially give clinicians
a false sense of security when considering the presumed future
clinical course of older patients with CF, while simultaneously
discouraging both physicians and patients when an individual
year-to-year change is observed to be negative. The loss of lung
function may incorrectly suggest that a patient has failed to fight
CF effectively enough to meet population-based expectations.
Among older patients with CF, survivor bias influences the
cross-sectional population measurement of FEV1. Death and
lung transplantation tend to remove patients with low lung
function from the population, thus minimizing the size of year-
to-year decrease in aggregated mean and median FEV1%.
However, this analysis explicitly conditions the calculation of
individual year-to-year change on those who survived to the
second year, thus providing an estimate of the tendency to lose
function among patients who survive to need further care
(which is the majority of patients for any age year in our study).
The positive emphasis on improving quality of care at CF
centers is currently guided by population statistics [21].
Improvements that preserve average lung function within a
center should improve individual lung function. However,
considering only nationally derived aggregated population data
may obscure the importance of individual year-to-year changes,especially among adult patients with CF. Within a specific CF
care center, there may be greater differences between center
statistics and individual patient statistics due to generally
increased variability in smaller groups. The addition or
subtraction of a single patient can substantially influence the
population results for a small group. Thus, care centers should
use population statistics to understand center-specific trends
with regard to quality improvement but should also carefully
observe the outcomes of interventions to improve lung function
for individual patients from year to year. Identification of those
patients with the greatest declines in lung function from one
year to the next may pinpoint those most in need of additional
attention.
The stability of the year-to-year changes in individuals, as
assessed by the sensitivity analyses performed, strongly
suggests that survivor bias (e.g., loss to follow-up, lung
transplantation, death), non-uniform data collection, and
different methods of FEV1% calculation are not the source of
our findings. However, other biases that we could not detect
could have influenced our results. Our study results varied
somewhat when different equation sets [21,28–30] were
employed for normalization of lung function. However,
regardless of equation set, we found consistently high rates of
decline among adolescents and persistence of decline through-
out our adult study population. Our study was not much affected
by varying normalization equations for lung function but rather
uncovered and high-lighted potential artifacts that may exist in
the understanding of lung function decline based on cross-
sectional studies that use different equations at different ages.
High FEV1% is an independent predictor of more rapid decline
in lung function, and that may have contributed, in part, to the
effect that we observed in children and adolescents aged 6 to
255T.G. Liou et al. / Journal of Cystic Fibrosis 9 (2010) 250–25617 years [33]. However, this effect is insufficient to explain
differences between aggregated and individual year-to-year
changes in lung function, especially among adults. We did not
evaluate the effects of treatment because these often depend on
FEV1%, the object of our study thus representing a potential
confounder to avoid. Nor did we evaluate outcomes other than
FEV1% for year-to-year changes because our goal was to better
understand and reflect the emphasis placed on FEV1% within
the CF community and the literature on CF [1,2,5,21,33].
Because our study was limited to patient ages 6 through 45, we
cannot comment on year-to-year changes for the very young or
the growing number of adults older than 45 with CF. Finally,
because of rapid and welcome advances in care for CF patients,
we cannot predict whether the adolescents that we studied will
eventually exhibit the same pattern of year-to-year changes that
we saw among the adults that we studied.
Cross-sectional observations of year-to-year change in lung
function are helpful for understanding the impact of therapy on
the aggregated population. We found, however, that individual
year-to-year changes can differ, sometimes dramatically, from
national and local aggregated changes in lung function. These
observations regarding year-to-year individual trends in lung
function for a wide range of patient ages provide information
relevant to decision making in clinical practice especially to
adapt to individual patient needs.
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